Last reviewed · How we verify

NCT02475382: CheckMate 169

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

NO LONGER AVAILABLE Last updated 27 November 2020
What this trial tests

trial testing Nivolumab in Squamous Non-Small Cell Lung Cancer. No longer available.

Quick facts

Lead sponsorBristol-Myers Squibb
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS
Sites50 locations across Canada, Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Squamous Non-Small Cell Lung Cancer or Non-squamous Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous (Sq) or non-squamous (non-Sq) non-small cell lung cancer (NSCLC) , Stage IIIB/IV and whose physicians believe that nivolumab treatment is appropriate.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Current and Future Clinical Applications of ctDNA in Immuno-Oncology.
    Stadler JC, Belloum Y, Deitert B, Sementsov M, et al · · 2022 · cited 123× · PMID 34815256 · DOI 10.1158/0008-5472.can-21-1718
  2. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
    Ottonello S, Genova C, Cossu I, Fontana V, et al · · 2020 · cited 64× · PMID 32117275 · DOI 10.3389/fimmu.2020.00125
  3. Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.
    Alama A, Coco S, Genova C, Rossi G, et al · · 2019 · cited 46× · PMID 31295929 · DOI 10.3390/jcm8071011
  4. Comparison Between <sup>18</sup>F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, et al · · 2020 · cited 35× · PMID 31806768 · DOI 10.2967/jnumed.119.233056
  5. Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience.
    Monaco L, Gemelli M, Gotuzzo I, Bauckneht M, et al · · 2021 · cited 28× · PMID 33915801 · DOI 10.3390/cancers13071634
  6. International consensus on radiotherapy in metastatic non-small cell lung cancer.
    Zhu Z, Ni J, Cai X, Su S, et al · · 2022 · cited 27× · PMID 36248338 · DOI 10.21037/tlcr-22-644
  7. The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab.
    Bauckneht M, Genova C, Rossi G, Rijavec E, et al · · 2021 · cited 25× · PMID 34206545 · DOI 10.3390/cancers13133117
  8. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
    Genova C, Boccardo S, Mora M, Rijavec E, et al · · 2019 · cited 21× · PMID 31581482 · DOI 10.3390/jcm8101566

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

Other recruiting trials for Squamous Non-Small Cell Lung Cancer

Currently open trials in the same condition.

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02475382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing